Tissue Inhibitor of Metalloproteinase-1
Research News and Information

Saturday, November 21, 2009

Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction.

13 Sep 2009 BACKGROUND: Targeted delivery of mesenchymal precursor cells (MPCs) can modify left ventricular (LV) cellular and extracellular remodeling after myocardial infarction (MI). However, whether and to what degree LV remodeling may be affected by MPC ... Read more...

Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas.

30 Aug 2009 AIMS: The balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) is involved in the morphogenesis of normal salivary gland as well as in the mechanisms of tumour invasion and metastasis. The role of MMPs and TIMPs in ... Read more...

In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis.

30 Aug 2009 PURPOSE: Matrix metalloproteinases (MMPs) have a role in the pathogenesis of rosacea-associated chronic blepharitis. Doxycycline is largely used as a treatment for recalcitrant chronic blepharitis. It has been shown in vitro that doxycycline ... Read more...

Latest indexed articles for 'Tissue Inhibitor of Metalloproteinase-1'

These are the very latest articles for this heading:

• Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. 13 Sep 2009
• Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. 30 Aug 2009
• In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. 30 Aug 2009
• Peritumoral administration of GPI-anchored TIMP-1 inhibits colon carcinoma growth in Rag-2 gamma chain-deficient mice. 30 Aug 2009
• Matrix metalloproteinase-26 is present more frequently in squamous cell carcinomas of immunosuppressed compared with immunocompetent patients. 30 Aug 2009
• Differential regulation of blood vessel formation between standard and delayed bone healing. 30 Aug 2009
• In vivo remodeling of intervertebral discs in response to short- and long-term dynamic compression. 30 Aug 2009
• Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. 25 Aug 2009
• Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. 16 Aug 2009
• Collagen I regulates matrix metalloproteinase-2 activation in osteosarcoma cells independent of S100A4. 11 Aug 2009
• IL-10 is a negative regulatory factor of CAWS-vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice. 10 Aug 2009
• Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer. Aug 2009
• Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. 30 Jul 2009
• Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression. 30 Jul 2009
• Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. 30 Jul 2009
• Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions. 30 Jul 2009
• Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. 30 Jul 2009
• Sialic acid reduces acute endotoxemia-induced liver dysfunction in the rat. 30 Jul 2009
• Cancer cell growth and extracellular matrix remodeling mechanism of ascorbate; beneficial modulation by P. leucotomos. 30 Jul 2009
• Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Tissue Inhibitor of Metalloproteinase-1'

Definition: A member of the family of TISSUE INHIBITOR OF METALLOPROTEINASES. It is a N-glycosylated protein, molecular weight 28 kD, produced by a vast range of cell types and found in a variety of tissues and body fluids. It has been shown to suppress metastasis and inhibit tumor invasion in vitro.

Registry Number: 0

Descriptor UI: D019715

Alternative terms: Tissue Inhibitor of Metalloproteinase-1; Metalloproteinase-1 Tissue Inhibitor; Tissue Inhibitor of Metalloproteinase 1; TIMP-1;

Allowable Qualifiers: blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists; administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis;

Tree Number: D12.776.926.450;

History Note: 98; see TISSUE-INHIBITOR OF METALLOPROTEINASE-1 (NM) 1980-97